Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Share-based Compensation (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Share-based Compensation for 6 consecutive years, with -$1000.0 as the latest value for Q4 2018.

  • Quarterly Share-based Compensation rose 97.96% to -$1000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $142000.0 through Dec 2018, down 72.64% year-over-year, with the annual reading at $2.6 million for FY2025, 9.78% down from the prior year.
  • Share-based Compensation hit -$1000.0 in Q4 2018 for Armata Pharmaceuticals, down from $8000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q3 2014 to a low of -$714000.0 in Q4 2014.
  • Historically, Share-based Compensation has averaged $215100.0 across 5 years, with a median of $160000.0 in 2015.
  • Biggest five-year swings in Share-based Compensation: plummeted 149.69% in 2014 and later soared 1469.23% in 2016.
  • Year by year, Share-based Compensation stood at -$714000.0 in 2014, then soared by 132.21% to $230000.0 in 2015, then grew by 29.13% to $297000.0 in 2016, then tumbled by 116.5% to -$49000.0 in 2017, then skyrocketed by 97.96% to -$1000.0 in 2018.
  • Business Quant data shows Share-based Compensation for ARMP at -$1000.0 in Q4 2018, $8000.0 in Q3 2018, and $13000.0 in Q2 2018.